• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管内皮生长因子基因多态性和单倍型与女性双膦酸盐相关性颌骨骨坏死。

Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.

机构信息

Department of Biomedical Sciences and Human Oncology, Oral Medicine Section, University of Turin, Turin, Italy.

出版信息

J Oral Pathol Med. 2011 Jul;40(6):510-5. doi: 10.1111/j.1600-0714.2010.01004.x. Epub 2011 Jan 20.

DOI:10.1111/j.1600-0714.2010.01004.x
PMID:21251073
Abstract

OBJECTIVE

To investigate the polymorphisms of the vascular endothelial growth factor (VEGF) gene in relation to female patients who developed bisphosphonate-related osteonecrosis of the jaws (BRONJ).

METHODS

Test subjects were 30 Italian female patients with BRONJ (Group A). Control subjects were 30 female patients with a history of intravenous bisphosphonate use without any evidence of osteonecrosis (Group B) and 125 unrelated healthy volunteers (Group C). Three single-nucleotide polymorphisms were investigated: -634 G>C, occurring in 5' untranslated region (UTR); +936 C>T, occurring in 3' UTR; and -2578 C>A of the promoter region.

RESULTS

The frequency of the VEGF CAC (+936/-2578/-634) haplotype was increased in patients with BRONJ, compared with female disease-negative controls [odds ratio (OR) = 2.76, 95% CI = 1.09-4.94, P = 0.039; corrected P value: P(c) = 0.117], and was also increased compared with female healthy controls (OR = 2.11, 95% CI = 1.14-3.89, P = 0.024; corrected P value: P(c) = 0.072). The CC homozygotes of -634G>C of VEGF gene and AA homozygotes of -2578C>A have also been significantly correlated in female patients who developed BRONJ compared with healthy controls (OR = 2.04, 95% CI = 1.12-3.70, P = 0.008; corrected P value: P(c) = 0.024).

CONCLUSIONS

These results suggest a possible haplotype effect of VEGF polymorphisms expression in BRONJ Italian female patients. Studies with different and larger populations possibly using TagSNP to represent all haplotypes within the VEGF gene are needed to further delineate the genetic contribution of this gene to BRONJ.

摘要

目的

研究血管内皮生长因子(VEGF)基因多态性与发生双膦酸盐相关性下颌骨坏死(BRONJ)的女性患者的关系。

方法

研究对象为 30 名意大利女性 BRONJ 患者(A 组)。对照组为 30 名有静脉内双膦酸盐使用史但无骨坏死证据的女性患者(B 组)和 125 名无关的健康志愿者(C 组)。研究了三个单核苷酸多态性:5'非翻译区(UTR)中的-634 G>C、3'UTR 中的+936 C>T 和启动子区域中的-2578 C>A。

结果

与 BRONJ 阴性女性疾病对照组相比,BRONJ 患者 VEGF CAC(+936/-2578/-634)单倍型的频率增加[比值比(OR)=2.76,95%置信区间(CI)=1.09-4.94,P=0.039;校正 P 值:P(c)=0.117],与女性健康对照组相比也增加(OR=2.11,95%CI=1.14-3.89,P=0.024;校正 P 值:P(c)=0.072)。与健康对照组相比,VEGF 基因-634G>C 的 CC 纯合子和-2578C>A 的 AA 纯合子在发生 BRONJ 的女性患者中也有显著相关性(OR=2.04,95%CI=1.12-3.70,P=0.008;校正 P 值:P(c)=0.024)。

结论

这些结果表明 VEGF 基因多态性表达在意大利女性 BRONJ 患者中可能存在单倍型效应。需要使用 TagSNP 代表 VEGF 基因内的所有单倍型进行不同和更大人群的研究,以进一步阐明该基因对 BRONJ 的遗传贡献。

相似文献

1
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.血管内皮生长因子基因多态性和单倍型与女性双膦酸盐相关性颌骨骨坏死。
J Oral Pathol Med. 2011 Jul;40(6):510-5. doi: 10.1111/j.1600-0714.2010.01004.x. Epub 2011 Jan 20.
2
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.遗传多态性和其他与双膦酸盐相关的颌骨骨坏死的风险因素。
Int J Oral Maxillofac Surg. 2011 Jun;40(6):605-11. doi: 10.1016/j.ijom.2011.02.002. Epub 2011 Mar 10.
3
Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.双膦酸盐相关颌骨骨坏死:乳腺癌患者危险因素的病例对照研究
J Clin Oncol. 2008 Oct 1;26(28):4634-8. doi: 10.1200/JCO.2008.16.2768. Epub 2008 Jun 23.
4
Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.静脉注射双膦酸盐治疗与双膦酸盐相关的颌骨坏死
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):44-52. doi: 10.1016/j.joms.2008.12.004.
5
Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.用于预测接受双膦酸盐治疗患者颌骨坏死发生情况的血清学骨标志物。
J Oral Maxillofac Surg. 2010 Sep;68(9):2241-7. doi: 10.1016/j.joms.2010.05.043.
6
Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.双膦酸盐相关骨坏死:遗传和后天危险因素
Oral Dis. 2009 Sep;15(6):382-7. doi: 10.1111/j.1601-0825.2009.01568.x. Epub 2009 Apr 22.
7
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.一项回顾性研究评估了 576 例接受静脉注射双膦酸盐的癌症患者颌骨坏死的频率和风险因素。
Am J Clin Oncol. 2012 Aug;35(4):386-92. doi: 10.1097/COC.0b013e3182155fcb.
8
The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.手术切除在双膦酸盐相关颌骨骨坏死治疗中的作用。
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):85-95. doi: 10.1016/j.joms.2009.01.006.
9
[Clinical investigation of bisphosphonate-related osteonecrosis of the jaws].双膦酸盐相关颌骨坏死的临床研究
Gan To Kagaku Ryoho. 2009 Dec;36(13):2587-92.
10
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.接受双膦酸盐治疗的肿瘤患者颌骨骨坏死:一家口腔肿瘤转诊中心的前瞻性经验
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Aug;112(2):195-202. doi: 10.1016/j.tripleo.2011.02.037. Epub 2011 May 31.

引用本文的文献

1
Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.药物相关性颌骨坏死的遗传背景:当前证据和未来展望。
Int J Mol Sci. 2024 Sep 29;25(19):10488. doi: 10.3390/ijms251910488.
2
Interactive Associations between and and Bisphosphonate-Related Osteonecrosis of the Jaw in Patients with Osteoporosis.骨质疏松症患者中[具体内容缺失]与[具体内容缺失]及双膦酸盐相关颌骨坏死之间的交互关联。
Pharmaceuticals (Basel). 2023 Jul 21;16(7):1035. doi: 10.3390/ph16071035.
3
Identification of Potentially Pathogenic Variants Associated with Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ) Patients Using Whole-Exome Sequencing.
使用全外显子组测序鉴定与颌骨药物相关性骨坏死(MRONJ)患者复发相关的潜在致病变异体。
J Clin Med. 2022 Apr 12;11(8):2145. doi: 10.3390/jcm11082145.
4
Mechanism, prevention, and treatment for medication-related osteonecrosis of the jaws.药物相关性颌骨坏死的发生机制、预防及治疗。
Hua Xi Kou Qiang Yi Xue Za Zhi. 2021 Jun 1;39(3):245-254. doi: 10.7518/hxkq.2021.03.001.
5
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.转移性癌症接受双磷酸盐治疗患者的颌骨坏死的风险因素。
Oral Dis. 2022 Jan;28(1):193-201. doi: 10.1111/odi.13746. Epub 2020 Dec 14.
6
Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: a case control study.鉴定癌症和骨质疏松症患者药物相关性颌骨坏死的遗传变异:病例对照研究。
J Transl Med. 2019 Nov 20;17(1):381. doi: 10.1186/s12967-019-2129-3.
7
Circulating microRNA Panel as a Novel Biomarker to Diagnose Bisphosphonate-Related Osteonecrosis of the Jaw.循环 microRNA 谱作为一种新型生物标志物用于诊断双膦酸盐相关性颌骨骨坏死。
Int J Med Sci. 2018 Nov 22;15(14):1694-1701. doi: 10.7150/ijms.27593. eCollection 2018.
8
Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.结直肠癌患者中与贝伐单抗治疗相关的颌骨骨坏死延迟诊断:两例报告
Dent J (Basel). 2016 Oct 29;4(4):39. doi: 10.3390/dj4040039.
9
Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.长期静脉注射双膦酸盐治疗停药后双膦酸盐相关颌骨坏死患者的骨转换和血管生成血清标志物
J Oral Maxillofac Surg. 2016 Apr;74(4):738-46. doi: 10.1016/j.joms.2015.09.028. Epub 2015 Oct 3.
10
Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics.通过全外显子组测序和生物信息学对双膦酸盐相关颌骨坏死(BRONJ)进行遗传学研究。
PLoS One. 2015 Feb 10;10(2):e0118084. doi: 10.1371/journal.pone.0118084. eCollection 2015.